DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Eisenberger M, Hardy-Bessard AC, Kim CS. et al
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
J Clin Oncol 2017;
35: 3198-3206 . doi:10.1200/jco.2016.72.1076
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.